三元生物 reported revenue of ¥0.43B for the period ended 2026-06-30, +34.8% year on year. Net income was ¥0.05B, a 11.8% net margin on a 17.6% gross margin. The largest revenue line is 糖醇类 at 70% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.43B | +34.8% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.05B | -12.2% |
| Gross margin | 17.6% | Net margin 11.8% |
| Revenue Q/Q | -9.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 糖醇类 | ¥0.30B | 70.0% |
| 功能糖类 | ¥0.09B | 20.6% |
| 其他类 | ¥0.04B | 9.0% |
| 糖苷类 | ¥0.00B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.35B | 82.4% |
| R&D | ¥0.02B | 4.4% |
| SG&A | ¥0.02B | 4.4% |
| Tax & other | ¥0.01B | 1.7% |
| Item | Amount |
|---|---|
| Total assets | ¥4.48B |
| Total liabilities | ¥0.29B |
| Shareholders' equity | ¥4.19B |
| Equity / assets | 93.5% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 146% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学 ・ 观想科技 ・ 中汽股份 ・ 万凯新材 ・ 铜冠铜箔 ・ 华是科技 ・ 腾远钴业
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies